Study identifies biomarker for breast cancer response to immunotherapy
Grant strengthens breast cancer research efforts
A critical factor for wound healing
Breast cancer-killing RIG
Study seeks to boost breast tumor immune response
Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.
Study to test combination therapy for breast cancer
Study explores how some breast cancers resist treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. The new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified gene alterations […]
Study details rare heart risk of certain cancer therapies
Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […]
Breast cancer program lands new research grants
Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. The grants totaling more than $3 million will fund mechanistic science and clinical trials designed to test novel therapy combinations and determine why some forms of breast cancer become resistant […]
Pagination
- Page 1
- Next page